Most Read Articles
13 Sep 2020
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
5 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


Four osteoporosis medications effective against vertebral, hip fractures

Jairia Dela Cruz
07 Nov 2019

The osteoporosis medications teriparatide (TPTD), romosozumab (ROMO), raloxifene (RLX) and denosumab (DEN) all confer significant benefits for reducing vertebral and hip fractures and inducing changes in bone mineral density at the femoral neck (FN BMD) as compared with placebo, according to the results of a network meta-analysis (NMA).

“This finding complements previous NMAs that have shown benefit on vertebral fracture risk for bisphosphonates, RLX, DEN and TPTD,” the investigators said. [Bone 2016;89:52-58; J Cell Biochem 2018;119:4469-4481; J Clin Endocrinol Metab 2012;97:1871-1880]

“[However], unlike other[s], this article includes the newer drug ROMO within an NMA against the nonbisphosphonates and bisphosphonates currently recommended for UK treatment,” they added. [https://www.nice.org.uk/guidance/ta70; https://www.nice.org.uk/Guidance/TA161]

The current NMA included 46 randomized controlled trials (RCTs) of nonbisphosphonates (DEN, RLX, ROMO and TPTD) and 49 RCTs of bisphosphonates (alendronate, risedronate, ibandronate and zoledronic acid) in a population at risk of osteoporotic fracture. Most of the trials involved postmenopausal women, although some were conducted in men and in cohorts with steroid-induced osteoporosis.

Pooled data (46 RCTs) revealed that all four nonbisphosphonates drugs studied had favourable effects on the risk of vertebral fractures relative to placebo. The hazard ratios [HRs] were 0.23 (95 percent credible internal [CrI], 0.16–0.32) with TPTD, 0.25 (95 percent CrI, 0.15–0.43) with ROMO for 1 year followed by the bisphosphonate alendronate, 0.30 (95 percent CrI, 0.21–0.43) with DEN, and 0.61 (95 percent CrI, 0.44–0.80) with RLX. [Bone 2019;doi:10.1016/j.bone.2019.115081]

For the risk of hip fractures, the pooled results (23 RCTs) showed TPTD, ROMO/ALN and DEN to exert beneficial treatment effects compared with placebo. TPTD was associated with the greatest treatment effect (HR, 0.35, 95 percent CrI, 0.15–0.73), with the highest probability of being the best treatment (0.50), although there was insufficient evidence to differentiate between TPTD and the other active treatments.

Finally, pooled data for FN BMD (73 RCTs) indicated that all treatments conferred meaningful benefits relative to placebo. ROMO/ALN showed the largest effect size (mean difference, 6.08, 95 percent CrI, 4.25–7.91), had the highest probability of being the best treatment (0.96), and was considerably more effective than all active treatments.

The NMA had several limitations, including restriction to English language publications, lack of study arms to connect the networks, differences in experience of fracture at baseline in populations, and the inability to address timing of treatment benefit after index fracture.

The investigators noted a moderate heterogeneity for all NMAs. They tested the consistency between direct and indirect evidence and found no strong evidence for inconsistency. “A sensitivity analysis for vertebral fracture rate, removing lower quality studies from the NMA, gave results consistent with the main analysis.

“Other sensitivity analyses conducted to assess the impact of assessment method for vertebral fractures (radiographic or clinical), and effect of prior bisphosphonate treatment, demonstrated that the results of the NMA were robust to these potential issues,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Sep 2020
Regardless of birth weight, being obese at preschool age is associated with a greater risk of elevated blood pressure during early childhood, a recent China study has found. A longer duration of breastfeeding appears to help mitigate such a risk.
Jairia Dela Cruz, 4 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
5 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.